Ribociclib
- Generic Name
- Ribociclib
- Brand Names
- Kisqali 200 Mg Daily Dose Carton, Kisqali Femara Co-pack, Kisqali
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30N8O
- CAS Number
- 1211441-98-3
- Unique Ingredient Identifier
- TK8ERE8P56
- Background
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring tha...
- Indication
用于联合芳香酶抑制剂或氟维司群治疗激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的晚期或转移性乳腺癌成人患者。
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer
- Associated Therapies
- -
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2022-01-21
- Target Recruit Count
- 7
- Registration Number
- NCT02586675
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 30
- Registration Number
- NCT02571829
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
- Conditions
- Interventions
- Drug: EnzalutamideDrug: RibociclibOther: Laboratory Biomarker AnalysisOther: Pharmacological StudyProcedure: Biospecimen CollectionProcedure: BiopsyProcedure: EchocardiographyProcedure: Multigated Acquisition ScanProcedure: Bone ScanProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2024-05-13
- Target Recruit Count
- 46
- Registration Number
- NCT02555189
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
- Conditions
- Interventions
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Rahul Aggarwal
- Target Recruit Count
- 43
- Registration Number
- NCT02494921
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 726
- Registration Number
- NCT02422615
- Locations
- 🇺🇸
UCLA Medical Center ., Los Angeles, California, United States
🇺🇸Florida Cancer Research Institute Dept of Oncology, Davie, Florida, United States
🇺🇸UF Health Cancer Center at Orlando Health, Orlando, Florida, United States
Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
- Conditions
- Interventions
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT02420691
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-04-13
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT02414724
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Detect V / CHEVENDO (Chemo vs. Endo)
- Conditions
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Prof. Wolfgang Janni
- Target Recruit Count
- 271
- Registration Number
- NCT02344472
- Locations
- 🇩🇪
University Hospital Ulm Gynecology/Obstetrics, Ulm, Germany
Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2018-06-07
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 3
- Registration Number
- NCT02345824
- Locations
- 🇺🇸
University of Virginia Health System, Charlottesville, Virginia, United States
Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT02292550
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.